Secura Bio was established in 2019 with a singular mission: to close the gap between innovative oncology therapies and the patients who need them most. Our high-touch approach is informed by our decades of experience shaping the impact of oncology’s largest clinical and market opportunities. We know that true impact comes from personalization and an unwavering commitment to serve patients and expand the possibilities of life-prolonging oncology medicines.

About the Role

We are seeking a talented and motivated Manager, Clinical Supply to join Secura Bio. The ideal candidate will lead the planning, execution, and oversight of clinical supply activities supporting global clinical development programs. The role is responsible for ensuring reliable product supply, coordinating cross-functional activities, and maintaining operational readiness across internal teams and external partners.

This role requires a high degree of ownership, responsiveness, and independent decision-making. The successful candidate will serve as a key liaison among Clinical Operations, Quality Assurance, Regulatory Affairs, contract manufacturers, depots, packaging vendors, and logistics providers. They will be expected to proactively identify and mitigate risks, communicate issues and priorities in a timely manner, and ensure continuity of clinical supply operations through effective planning and execution.

Employment Type

Full-time

Reports To

Senior Director, Technical Operations

Key Responsibilities

Lead end-to-end clinical supply planning and execution for assigned clinical programs to ensure uninterrupted product availability throughout all phases of study conduct.
Develop and maintain clinical supply strategies, including forecasting, inventory planning, manufacturing, packaging, distribution, and contingency planning.
Serve as the primary owner and point of accountability for clinical supply activities, ensuring deliverables, milestones, and commitments are executed on time and to a high standard.
Proactively identify, communicate, and mitigate supply chain risks that could impact study timelines, product availability, regulatory compliance, or operational execution.
Act as the primary liaison among Clinical Operations, Quality Assurance, Regulatory Affairs, Finance, contract manufacturers, packaging vendors, depots, and distribution partners to ensure alignment and timely execution of supply activities.
Provide effective oversight of contract manufacturers, vendors, and logistics providers, driving issue resolution, accountability, and continuous improvement.
Maintain timely and effective communication with internal and external stakeholders, including routine status updates, issue escalation, and management reporting.
Manage domestic and international clinical supply logistics and distribution activities, ensuring compliance with applicable regulatory and quality requirements.
Support clinical supply budgeting, forecasting, inventory optimization, and strategic planning activities.
Support Quality System activities related to clinical supply operations, including change controls, investigations, documentation, inspections, and continuous improvement initiatives.

Required Qualifications

Bachelor's degree in Life Sciences, Supply Chain, Engineering, Business, or a related discipline, or equivalent combination of education and experience.
Minimum five (5) years of experience in clinical supply chain, pharmaceutical manufacturing, CMC operations, or related pharmaceutical operations.
Demonstrated experience developing and executing clinical supply strategies, including forecasting, inventory management, manufacturing planning, packaging, distribution, and vendor management.
Strong knowledge of pharmaceutical manufacturing, clinical supply chain operations, cGMP requirements, GDP principles, and applicable regulatory requirements.
Proven ability to independently manage multiple complex projects, drive execution of deliverables, and maintain accountability for results in a fast-paced environment.
Demonstrated ability to proactively identify risks, develop mitigation strategies, and effectively communicate and escalate issues to stakeholders and management.
Excellent communication, stakeholder management, and cross-functional leadership skills, with the ability to influence internal teams and external partners to achieve business objectives.

Preferred Qualifications

Experience leading clinical supply operations for global Phase II and Phase III clinical studies.
Experience working in a small or emerging biotechnology company environment with a high degree of independence and accountability.
Experience managing external contract manufacturers, packaging vendors, depots, IRT providers, and global logistics partners.
Knowledge of clinical supply systems and tools, including IRT/RTSM platforms, inventory management systems, serialization technologies, and clinical trial logistics processes.
Demonstrated ability to utilize digital tools, data analytics, automation, and artificial intelligence solutions to improve planning, forecasting, reporting, communication, and operational efficiency.
Project Management Professional (PMP), APICS/ASCM, Supply Chain, or related professional certification preferred.

Salary

$114,000 - $140,000

[]

About the company

Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$55M

Headquarters

Berkeley Heights, New Jersey

Founded

2019

Get referred to Secura Bio

See people who can refer or advise you

Simplify's Take

What believers are saying

U.S. COPIKTRA sales grew over 30% annually by November 2025.
Dec. 2025 TERZO enrollment hit 35 of 124 patients, keeping early-2027 readout alive.
Apr. 2026 JCO publication and Dec. 2025 NCCN CTCL update reinforce physician awareness.

What critics are saying

EMA withdrew Copiktra's EU authorization on Feb. 16, 2026, eliminating European commercialization.
COPIKTRA's label warns of treatment-related mortality in CLL/SLL, constraining adoption.
Secura remains concentrated in one drug; a TERZO failure would crush the company.

What makes Secura Bio unique

Secura Bio commercializes COPIKTRA, the first U.S.-approved dual PI3K-delta/gamma inhibitor.
Apr. 27, 2026 PRIMO data showed 48% ORR and 33.3% CRR in PTCL.
TERZO spans 45 sites across ten European countries, giving rare nTFHL development reach.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↓ -1%

2 year growth

↑ 0%

GlobeNewswire

Feb 11th, 2026

Secura Bio Expands Chief Financial Officer Will Brown's Leadership Role to Include Chief Operating Officer

Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. February 11, 2026 07:00 ET | Source: Secura Bio BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]

Secura Bio

Feb 11th, 2026

Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer.

Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. BERKELEY HEIGHTS, NJ, February 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]

GlobeNewswire

Nov 14th, 2024

Secura Bio Appoints Dr. Patrick Vink As Chairman Of The Board Of Directors

SUMMERLIN, Nev., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, is pleased to announce the appointment of Dr. Patrick Vink, a global biopharmaceutical executive experienced in development, marketing, and commercialization, as Chairman of its Board of Directors.Dr. Vink brings over 35 years of industry experience and currently serves as Chairman and Board member of several public and private biopharma companies, both in the U.S. and in Europe, including F2G Ltd and Essential Pharma

PR Newswire

Oct 15th, 2024

Secura Bio Appoints Charles R. Romp as Its Chief Executive Officer

Its product, COPIKTRA(R), is currently approved for the treatment of multiple B-cell malignancies and is also being developed for the treatment of peripheral T-cell lymphoma, for which it has received Fast Track status in the United States and is being investigated in combination with other agents through investigator-sponsored studies.